Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 10/20 | 0.47 |
| ▸ | NOTCH3 | Q9UM47 | 6/20 | 0.47 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.43 |
| ▸ | STK10 | O94804 | 2/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15608316 | 0.89 | NOTCH1 (0.55) | NOTCH1NOTCH3RBPJALDH1A1HPGD | |
| SCHEMBL15622403 | 0.88 | NOTCH1 (0.49) | NOTCH1NOTCH3RBPJALDH1A1 | |
| SCHEMBL15622381 | 0.88 | NOTCH1 (0.49) | NOTCH1NOTCH3RBPJALDH1A1 | |
| SCHEMBL15608340 | 0.88 | NOTCH1 (0.56) | NOTCH1NOTCH3RBPJSTK10SLK | |
| SCHEMBL18174929 | 0.87 | NOTCH1 (0.48) | NOTCH1NOTCH3RBPJSTK10SLK | |
| SCHEMBL17030701 | 0.87 | NOTCH1 (0.46) | NOTCH1NOTCH3RBPJCREBBP | |
| SCHEMBL15622374 | 0.86 | NOTCH1 (0.51) | NOTCH1NOTCH3RBPJMAPK10 | |
| SCHEMBL15608509 | 0.85 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL15608508 | 0.85 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL17030708 | 0.84 | NOTCH1 (0.42) | NOTCH1NOTCH3RBPJ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897947-B1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 61/4885NOTCH3 34/4885RBPJ 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.